Cue Biopharma, Inc.
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
CUE | NDAQ
Overview
Corporate Details
- ISIN(s):
- US22978P1066
- LEI:
- Country:
- United States of America
- Address:
- 40 GUEST STREET, 2135 BOSTON
- Website:
- https://www.cuebiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a novel class of injectable biologics to selectively engage and modulate disease-specific T cells. The company's proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform engineers therapeutics designed to mimic natural immune signals. This approach aims to selectively expand and activate specific immune cells directly within the patient's body, mobilizing the immune system to treat serious diseases. Cue Biopharma's pipeline focuses on developing precision immunotherapies for oncology and autoimmune and inflammatory diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cue Biopharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cue Biopharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cue Biopharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
